Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Merry et al. 2017

This clinical trial evaluated multiwavelength photobiomodulation—primarily 670 nm (4–7.7 J/cm²), supplemented with 590 nm and 790 nm (0.1 J/cm²)—in patients with atrophic AMD. Across a 3-week treatment period, participants demonstrated reduced drusen volume, improved best-corrected visual acuity, and improved contrast sensitivity, with excellent tolerability and no significant adverse effects.